RecruitingPhase 2NCT05190705
Loncastuximab Tesirine in WM
Studying Waldenström macroglobulinemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Shayna Sarosiek, MD
- Principal Investigator
- Shayna Sarosiek, MDDana-Farber Cancer Institute
- Intervention
- Loncastuximab Tesirine(drug)
- Enrollment
- 36 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2028
Study locations (4)
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Fred Hutch, Seattle, Washington, United States
Collaborators
ADC Therapeutics S.A.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05190705 on ClinicalTrials.govOther trials for Waldenström macroglobulinemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07387471Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)AbbVie
- RECRUITINGPHASE2NCT05099471Efficacy of Venetoclax in Combination With Rituximab in Waldenström's MacroglobulinemiaChristian Buske
- RECRUITINGPHASE2NCT06561347Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WMMassachusetts General Hospital
- RECRUITINGNCT05093153Spanish Registry of Patients With IgM Monoclonal GammopathiesFundación Española de Hematología y Hemoterapía
- ACTIVE NOT RECRUITINGPHASE2NCT04624906Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's MacroglobulinemiaSunnybrook Health Sciences Centre
- ACTIVE NOT RECRUITINGPHASE2NCT04273139Ibrutinib + Venetoclax in Untreated WMDana-Farber Cancer Institute
- RECRUITINGPHASE2, PHASE3NCT04061512Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's MacroglobulinaemiaUniversity College, London
- ACTIVE NOT RECRUITINGPHASE1NCT01209871Vaccine Therapy in Treating Patients With Lymphoplasmacytic LymphomaM.D. Anderson Cancer Center